ClinicalTrials.gg
RecruitingNCT07513506Updated Oct 20, 2026

Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)

An interventional study of Extensively hydrolyzed casein formula (C-eHCF), commercially available and Extensively hydrolyzed casein formula (INV-eHCF) in Growth, sponsored by Mead Johnson Nutrition. Recruiting at 12 sites in United States. Open to participants aged 10 Days to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Mead Johnson Nutrition (part of Reckitt) · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 20, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
10 Days to 14 Days
Sex
All
01

Study summary

This is a research study to compare an investigational infant formula against a currently marketed infant formula. An investigational infant formula is one that has never been approved by the United States Food and Drug Administration (FDA).

The purpose of this research study is to evaluate the growth and tolerance of infants who consume a new (not yet available to buy) extensively hydrolyzed cow milk protein infant formula compared to an extensively hydrolyzed cow milk protein infant formula that is currently available to buy. The study will also look at the growth of your baby, how many poops your baby has, what the poops are like (for example, soft or hard), how much study formula your baby drinks, how well your baby handles the study formula (such as spit-up, fussiness, gas, colic, or changes in sleep), and any health problems that might come up during the study.

Read the detailed description

The current study is designed to demonstrate that an investigational extensively hydrolyzed casein formula developed utilizing a new manufacturing process, is well-accepted, tolerated and supports typical growth similar to a control extensively hydrolyzed casein formula in term, healthy infants from approximately 14 to 126 days of age. This formula has been determined to have a high-quality protein similar to that of intact casein, as seen in the protein efficiency ratio (PER) study. Secondary objectives will include tolerance, intake and stool characteristics between infants assigned to receive the control or the investigational formula through approximately 126 days of age. Control and investigational formulas have the same nutritional composition per 100 kcal.

02

Conditions studied

  • Growth
03

In context

Lead sponsor

Mead Johnson Nutrition is the lead sponsor of 58 studies on the registry; 1 is open to participants now.

First submitted after Mead Johnson Nutrition became part of Reckitt.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Days to 14 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 10 to 14 days of age at randomization, inclusive (day of birth is considered Day 0)
  • Singleton birth
  • Gestational age of 37 weeks + 0 days to 41 weeks + 6 days, inclusive
  • Birth weight of 2500 g to 4200 g, inclusive
  • Birth weight appropriate for gestational age (AGA, defined as birth weight-for-age between 10th and 90th percentile, inclusive)
  • Exclusively receiving infant formula for at least 24 hours prior to randomization
  • Parent(s) or legal guardian(s) have full intention to exclusively feed their infant study formula through 126 days of age
  • Signed obtained from parent or legal guardian for infant's participation in the study
  • Signed authorization obtained from parent or legal guardian to use and/or disclose Protected Health Information for the infant from birth through the length of the study period
  • Parent or legal guardian agrees not to enroll the infant in another interventional clinical study while participating in this study
  • Decentralized participant's parent/caregiver or legal guardian has access to reliable internet and technology for remote visits.
  • Decentralized participant's parent/caregiver or legal guardian anticipates having a second adult available for all remote visits.

Exclusion criteria

Exclusion Criteria:

  • History of underlying metabolic or chronic disease; congenital malformation; immunodeficiency, gastrointestinal condition, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food by mouth, the normal growth and development of the infant, or the evaluation of the infant
  • Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization
  • First degree relative (if known) history of cow's milk protein intolerance or allergy
  • Maternal history with known adverse effects on the fetus and/or newborn infant in the opinion of the investigator, such as, but not limited to diabetes, smoking, active tuberculosis, perinatal infection, or substance abuse
  • Weight at Visit 1 is \<98% of birth weight [weight at Visit 1÷ birth weight) x 100\< 98%]
  • Infants whose parent, legal guardian, or first-degree relative is an employee of MJN/Reckitt or an affiliated vendor (e.g., CRO, laboratory, or data management provider) involved in the clinical trial, and who is directly or indirectly engaged in the design, conduct, oversight, or analysis of the study; has access to confidential study information; or holds supervisory authority over personnel involved in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Active comparator
    Extensively hydrolyzed casein formula (C-eHCF), commercially available

    Other: Extensively hydrolyzed casein formula (C-eHCF), commercially available

  • Experimental
    Extensively hydrolyzed casein formula (INV-eHCF)

    Other: Extensively hydrolyzed casein formula (INV-eHCF)

Interventions

  • OtherExtensively hydrolyzed casein formula (C-eHCF), commercially available

    A commercially available extensively hydrolyzed casein formula

  • OtherExtensively hydrolyzed casein formula (INV-eHCF)

    An extensively hydrolyzed casein formula

06

What researchers measure

Primary outcomes

  1. Rate of weight gain (g/day)

    Time frame: up to 131 days of age

Secondary outcomes

  1. body length (cm)

    Time frame: up to 131 days of age

  2. Head Circumference (cm)

    Time frame: up to 131 days of age

  3. Body weight (g)

    Time frame: up to 131 days of age

  4. Growth z-scores

    head circumference-for-age

    Time frame: up to 131 days of age

  5. Growth Z Scores

    weight-for-age

    Time frame: up to 131 days of age

  6. Growth Z Scores

    Length-for-age

    Time frame: up to 131 days of age

  7. Stool characteristics

    Time frame: up to 131 days of age

  8. Study formula intake

    Time frame: up to 131 days of age

  9. Tolerance

    Time frame: up to 131 days of age

  10. Medically confirmed adverse events

    Time frame: up to 131 days of age

07

Study locations

11 of 12 sites recruiting
  • Alabama Clinical Therapeutics
    Birmingham, Alabama 35235, United States
    Recruiting
  • Alabama Clinical Therapeutics
    Birmingham, Alabama 35235, United States
    Recruiting
  • Childrens Clinic of Jonesboro
    Jonesboro, Arkansas 72401, United States
    Recruiting
  • SPRIM
    Harbor Beach, Florida 32937, United States
    Recruiting
  • Symphony Research
    Jacksonville, Florida 32224, United States
    Recruiting
  • Hope Research Network
    Virginia Gardens, Florida 33166, United States
    Not yet recruiting
  • Mid Valley Research Inc.
    Moline, Illinois 61265, United States
    Recruiting
    • Amie Khan · Contactnafeeskh20@gmail.com · (563) 528-4690
    • Nafees Khan, MD · Principal investigator
  • Springs Medical Research
    Owensboro, Kentucky 42303, United States
    Recruiting
    • Pam Yeiser · Contactyeiserps@gmail.com · 270-683-3232
    • Michael Yeiser, MD · Principal investigator
  • InnovoResearch
    Wilmington, North Carolina 28405, United States
    Recruiting
  • AVIATI Healthcare & Clinical Research
    Memphis, Tennessee 38115, United States
    Recruiting
    • Ashiqua Jackson · Contactaviatihealth@gmail.com · 901-482-3606
    • Katosha Muse, MD · Principal investigator
  • NeutraLife Science
    Richmond, Texas 77469, United States
    Recruiting
  • AMR
    Syracuse, Utah 84075, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2026 → Aug 2027 and completion May 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 7, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Aug 1, 2027was Dec 2026
CompletionEst.
Nov 1, 2027was May 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
11 sites changed recruiting status (10 now recruiting, 1 now not yet recruiting)
Show 11 sites
  • Alabama Clinical Therapeutics · Birmingham, United Statesno status→Recruiting
  • Childrens Clinic of Jonesboro · Jonesboro, United Statesno status→Recruiting
  • SPRIM · Harbor Beach, United Statesno status→Recruiting
  • Symphony Research · Jacksonville, United Statesno status→Recruiting
  • Hope Research Network · Virginia Gardens, United Statesno status→Not yet recruiting
  • Mid Valley Research Inc. · Moline, United Statesno status→Recruiting
  • Springs Medical Research · Owensboro, United Statesno status→Recruiting
  • InnovoResearch · Wilmington, United Statesno status→Recruiting
  • AVIATI Healthcare & Clinical Research · Memphis, United Statesno status→Recruiting
  • NeutraLife Science · Richmond, United Statesno status→Recruiting
  • AMR · Syracuse, United Statesno status→Recruiting
Oct 20, 2026
Start date
Apr 3, 2026→Apr 15, 2026 (actual)
Oct 20, 2026
Primary completion
Dec 1, 2026→Aug 1, 2027
Oct 20, 2026
Study completion
May 1, 2027→Nov 1, 2027
Oct 20, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Mid Valley Research Inc. · Moline, United StatesContact added n•••@gmail.com · •••4690Contact added (no phone or email listed)
  • Springs Medical Research · Owensboro, United StatesContact added y•••@gmail.com · •••3232Contact added (no phone or email listed)
  • AVIATI Healthcare & Clinical Research · Memphis, United StatesContact added a•••@gmail.com · •••3606Contact added (no phone or email listed)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    12 sites changed recruiting status (11 now recruiting, 1 now not yet recruiting)
    Show 12 sites
    • Alabama Clinical Therapeutics · Birmingham, United Statesno status→Recruiting
    • Alabama Clinical Therapeutics · Birmingham, United Statesno status→Recruiting
    • Childrens Clinic of Jonesboro · Jonesboro, United Statesno status→Recruiting
    • SPRIM · Harbor Beach, United Statesno status→Recruiting
    • Symphony Research · Jacksonville, United Statesno status→Recruiting
    • Hope Research Network · Virginia Gardens, United Statesno status→Not yet recruiting
    • Mid Valley Research Inc. · Moline, United Statesno status→Recruiting
    • Springs Medical Research · Owensboro, United Statesno status→Recruiting
    • InnovoResearch · Wilmington, United Statesno status→Recruiting
    • AVIATI Healthcare & Clinical Research · Memphis, United Statesno status→Recruiting
    • NeutraLife Science · Richmond, United Statesno status→Recruiting
    • AMR · Syracuse, United Statesno status→Recruiting
    Start date Apr 3, 2026→Apr 15, 2026 (now actual)
    Primary completion Dec 1, 2026→Aug 1, 2027
    Study completion May 1, 2027→Nov 1, 2027
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Mid Valley Research Inc. · Moline, United StatesContact added n•••@gmail.com · •••4690Contact added (no phone or email listed)
    • Springs Medical Research · Owensboro, United StatesContact added y•••@gmail.com · •••3232Contact added (no phone or email listed)
    • AVIATI Healthcare & Clinical Research · Memphis, United StatesContact added a•••@gmail.com · •••3606Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07513506
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Apr 15, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Amy Benson
Contact
amy.benson@reckitt.com
812-760-9939
Veronica Fabrizio, DO
study director · Mead Johnson Nutrition

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion